(SKYEY) (SKYEY) Stock Price, News & Analysis

Skyepharma Ltd, formerly Skyepharma PLC, is a drug delivery company engaged in the development of oral and inhalation products. The Company operates as an independent developer of complex pharmaceutical products for global markets. Its principal activities are the generation and development of product and drug delivery technology concepts, involving the application of its inhalation and oral technologies. It operates through the segment of development and supply of pharmaceutical products. It is also involved in the supply of products to its marketing partners, as in the case for flutiform and over seven oral products manufactured in its Lyon Facility. It operates primarily for respiratory applications. Its inhalation products include Relvar Ellipta/Breo Ellipta, Anoro Ellipta and Incruse Ellipta. Its oral products include RAYOS/LODOTRA, Requip Once-a-day, Xatral/Uroxatral, Madopar DR/Prolopa, Sular, ZYFLO CR, Paxil CR, Diclofenacratiopharm Uno, Triglide and Coruno.